VitMode
Mikroskopowy obraz struktury komórek roślinnychturek / Pexels
Guides

Quercetin as a Senolytic: What the First Human Studies of the Dasatinib + Quercetin Combination Show

Quercetin, the same flavonoid we covered in an earlier article in the context of allergic rhinitis, plays an entirely different, far more experimental role in aging biology: as part of a combination with the oncology drug dasatinib (the "D+Q" protocol), studied as a senolytic — a substance that selectively clears senescent cells. This is the first pair of senolytic compounds for which real data have been published showing a reduction in senescent cells in humans, not just in animals. We take a close look at what these first clinical trials actually showed, what role quercetin itself actually plays in them, and where the limits of this evidence lie.

Redakcja VitMode — Badania i biomarkerythe VitMode editorial team, no individual bylinesPublished13 min read
How this article was made
Author
Redakcja VitMode — Badania i biomarkery — the VitMode editorial team, no individual bylines
Method
Prepared from primary sources: clinical trials, meta-analyses and guidelines. We describe study findings separately from our interpretation.
Source verification
Cited PubMed papers are automatically checked for a matching identifier, title and publication year.
Medical review
none — this article has not been reviewed by a physician
Last updated

The content is educational and does not replace medical advice. Read the full editorial process

Table of contents

TL;DR — key takeaways

The same flavonoid, a completely different research context

In an earlier article on quercetin and allergic rhinitis, we described this flavonoid in the context of its potential antihistamine action, confirmed in one clinical trial in people with hay fever. This article covers a completely different, far more experimental application: quercetin as part of a senolytic combination, studied in the context of aging biology, not allergy. If you're looking for information about quercetin for hay fever, that earlier article is the right place — here we focus exclusively on its senolytic role.

Quercetin on its own shows moderate senolytic properties in laboratory studies, but in research practice it's rarely tested in this context on its own — most often it's combined with dasatinib, an oncology drug (a tyrosine kinase inhibitor) used to treat chronic myeloid leukemia. This combination, known in the literature as "D+Q" (dasatinib + quercetin), is today the best-studied pair of senolytic compounds in humans.

The first data showing a reduction in senescent cells in humans

A second pilot study — idiopathic pulmonary fibrosis

The researchers concluded that the pilot confirmed the feasibility of such a trial and gave preliminary indications that senolytics may ease physical dysfunction associated with IPF, justifying larger, randomized trials — but this is a conclusion about the need for further research, not about confirmed efficacy.

Personalized for you

Struggling with sleep?

Answer a few questions about your sleep, stress, diet, and lifestyle. VitMode will show you which areas might need the most attention and which supplements could be worth considering.

Takes about 2 minutesBased on scientific evidence
Check your profile

Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.

What is quercetin's actual role in these studies

Myth

The D+Q studies prove that quercetin is a strong, confirmed senolytic that can be used on its own with a similar effect.

Fact

None of the described studies tested quercetin alone, without dasatinib — so no conclusion about quercetin's standalone senolytic action in humans can be drawn from them. Data from animal and cellular models suggest that quercetin alone has moderate, weaker senolytic activity than dasatinib and targets a partly different set of cell-survival pathways, which is precisely the rationale for combining the two substances, not evidence that each alone produces a comparable effect.

This distinction has practical significance for anyone considering standalone quercetin supplementation while expecting the senolytic effect described in the context of D+Q studies — the available clinical data simply say nothing about this specific scenario, since it hasn't been tested in these trials.

Safety — dasatinib changes the risk balance

Frequently asked questions

There is no published clinical data on this — the available studies (kidney, lung) tested only the dasatinib+quercetin combination, not quercetin on its own. Data from animal and cellular models suggest that quercetin alone has weaker senolytic activity than in combination with dasatinib, but this hasn't been directly tested in clinical trials in humans.

It should not be used on your own without medical supervision — dasatinib is a prescription drug used standardly in oncology, with real side effects (myelosuppression, fluid retention). The protocols studied clinically in the context of senolysis are conducted under the supervision of research teams monitoring safety.

The earlier article covers quercetin used on its own in the context of allergic rhinitis, where one randomized clinical trial shows symptom improvement. This article covers a completely different application — quercetin as part of a senolytic combination with dasatinib, studied in the context of cellular aging, not allergy. These are two independent research contexts for the same substance.

No — this was a pilot study assessing primarily whether the D+Q protocol genuinely reduces markers of senescent cells in humans, not a clinical trial assessing the effect on kidney disease progression as a hard endpoint. In addition, a corrigendum was issued for the publication after a re-analysis of the data, which is a reason for additional caution when interpreting the results.

Researchers measured biochemical markers such as the proteins p16INK4A and p21CIP1 (indicators of cell-cycle arrest typical of senescence) and SASP factors — pro-inflammatory signals secreted by senescent cells, including interleukin-6 (IL-6) and matrix metalloproteinases (MMP-9, MMP-12). A reduction in these markers after D+Q treatment was the main result of both described pilot studies.

The idiopathic pulmonary fibrosis study showed no significant change in lung function over the short observation period, though researchers noted preliminary, promising signals regarding physical dysfunction that justify further, larger trials. Neither described study was designed to assess the effect on lifespan — such an endpoint would require a far longer observation period.

Current data don't support such a recommendation — the available clinical trials tested only the combination with dasatinib, a prescription drug with a different safety profile. Standalone quercetin supplementation hasn't been tested in this specific senolytic context in humans, so expecting an analogous effect has no scientific basis today.

Sources (3)

Sources are numbered. PubMed items are automatically verified (identifier, title, year).

  1. 1Hickson et al. 2019 — EBioMedicinePubMed
  2. 2Corrigendum to Hickson et al. 2019 — EBioMedicinePubMed
  3. 3Justice et al. 2019 — EBioMedicinePubMed
VM

Redakcja VitMode — Badania i biomarkery

VitMode editorial team — no individual bylines; content based on primary sources

VitMode Editorial — Lab Tests and Biomarkers is the VitMode editorial team responsible for: laboratory tests, interpreting results and ageing biomarkers. The team has no individual bylines — texts are prepared by VitMode editors from primary sources (clinical trials, meta-analyses, guidelines). Every cited PubMed paper is automatically checked for a matching identifier, title and publication year. The content is educational and does not replace medical advice. Factual errors can be reported in a comment under the post or through the contact form; corrections are made by the editorial team.

Explore the topic further

Related topics from the VitMode knowledge base — pick the area you care about.

This article

Quercetin as a Senolytic: What the First Human Studies of the Dasatinib + Quercetin Combination Show

Your learning path

Path: Quercetin as a Senolytic

0 of 3 read0%

  1. Learn the basics

  2. Related topics

Progress is saved in this browser only.

Start the path
Tools for this topic

Your entries stay in your browser and are never sent anywhere. This is a notebook, not a diagnostic tool — it does not diagnose or recommend treatment. Discuss results with your doctor.

Questions readers often ask

Short answers from related articles — click to read more.

How does this article differ from your earlier pieces on fisetin and quercetin as senolytics?

Our earlier articles on fisetin and on quercetin as senolytics introduce the basics of senescence and cover the same D+Q pilot trials from quercetin's perspective. This article goes deeper into why dasatinib specifically was…

From the article: Dasatinib and Quercetin (D+Q): Why an Oncology Drug Was Paired With a Flavonoid, and What It Actually Means
How does fisetin differ from quercetin as a senolytic?

Both are flavonoids studied in the context of senolysis, but in the Yousefzadeh et al. study (2018), fisetin proved to be a stronger senolytic than quercetin from the same group of 10 tested compounds. Quercetin, however, is much…

From the article: Fisetin as a Senolytic: What the Mouse Study Showed and Where Human Research Stands Today
What dose of quercetin was tested for allergic rhinitis?

In the Yamada et al. (2022) study, participants took a supplement containing 200 mg of quercetin daily for 4 weeks. Other doses or forms of quercetin haven't been tested this way, so a similar effect can't automatically be…

From the article: Quercetin and Allergic Rhinitis: What Does the Clinical Trial Show?
Is hyperbaric oxygen therapy covered by insurance?

For strictly medical indications (some chronic wound cases, decompression sickness, gas embolism), coverage may be possible at selected centers, depending on the indication and a doctor's referral — it's worth verifying this…

From the article: Hyperbaric Oxygen Therapy — What It Is and Does It Work?

Did not find your answer? Write to us — we do not give individual advice, but we can point to reliable sources. Ask the editors

Related knowledge base entries

Zbliżenie na elegancki zegar symbolizujący upływ czasu

Autophagy

An intracellular 'housekeeping' process that clears out damaged proteins and organelles, whose discovery earned a Nobel Prize — one of the key mechanisms studied in the context of slowing aging.

LongevityModerate evidence
Starsza osoba mierząca ciśnienie krwi cyfrowym aparatem w domu

Immunosenescence

The progressive, multi-directional remodeling of the immune system with age — not a simple 'weakening,' but a complex change that both lowers the ability to fight new threats and raises the baseline level of inflammation.

LongevityModerate evidence
Kolorowa, abstrakcyjna reprezentacja nici DNA symbolizująca naukę i genetykę

Telomeres and Telomerase

Protective 'caps' on the ends of chromosomes that shorten with every cell division — one of the most recognizable, though still imperfect, biomarkers of cellular aging.

LongevityModerate evidence
Kolorowa, abstrakcyjna reprezentacja nici DNA

TFEB

The transcription factor TFEB acts as a master on-off switch for autophagy and the production of new lysosomes in the cell — one of the best-characterized molecular nodes linking these two processes, studied as a potential target for interventions in aging.

LongevityModerate evidence
Kolorowy model molekularny ilustrujący pojęcia naukowe

Proteostasis

A cell's ability to maintain balance between protein production, correct folding, and degradation — a network of mechanisms whose capacity declines with age and is studied as one of the fundamental pillars of cellular aging.

LongevityModerate evidence
Dwoje naukowców prowadzących badania mikroskopowe w laboratorium

Lysosomal Health

Lysosomes — the cell's 'recycling centers' — accumulate unprocessed waste and lose capacity with age, a pattern increasingly described as one of the fundamental, shared denominators of cellular aging and a potential target for future interventions.

LongevityEarly-stage evidence